[HTML] frontiersin.org

[HTML][HTML] Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream …

W Kong, X Yang, Y Shu, S Li, B Song… - Frontiers in public …, 2023 - frontiersin.org
Background Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed
in the United States and China for use in patients with carbapenem-resistant Klebsiella …
被引用次数：2 相关文章
[HTML] nih.gov

[HTML][HTML] Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream …

W Kong, X Yang, Y Shu, S Li, B Song… - Frontiers in Public …, 2023 - ncbi.nlm.nih.gov
Background Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed
in the United States and China for use in patients with carbapenem-resistant Klebsiella …

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection.

W Kong, X Yang, Y Shu, S Li, B Song, K Yang - 2023 - cabidigitallibrary.org
Abstract Background: Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been
confirmed in the United States and China for use in patients with carbapenem-resistant …

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection.

W Kong, X Yang, Y Shu, S Li, B Song… - Frontiers in Public …, 2023 - europepmc.org
Background Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed
in the United States and China for use in patients with carbapenem-resistant Klebsiella …

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection

W Kong, X Yang, Y Shu, S Li… - Frontiers in public …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed
in the United States and China for use in patients with carbapenem-resistant Klebsiella …

[引用][C] Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae

W Kong, X Yang, Y Shu, S Li, B Song, K Yang - europepmc.org
Background: Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed
in the United States and China for use in patients with carbapenem-resistant Klebsiella …